Premium
Long‐Term Results of GnRH Analogue (Buserelin) Treatment in Girls with Central Precocious Puberty
Author(s) -
BRAUNER R.,
THIBAUD E.,
BISCHOF P.,
SIZONENKO PC.,
RAPPAPORT R.
Publication year - 1985
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1985.tb10062.x
Subject(s) - buserelin , medicine , precocious puberty , central precocious puberty , endocrinology , bone age , gonadotropin releasing hormone , gonadotropin , hormone , luteinizing hormone , agonist , receptor
. The GnRH analogue Buserelin was given for one year to six girls with central precocious puberty in a daily subcutaneous dose of 20 μg/kg/day. A decrease of plasma estradiol and vaginal maturation index to prepubertal values was obtained in 5 out of 6 cases. Bone maturation decreased and final predicted adult height improved significantly. This analogue of GnRH appears to be an effective medication for gonadotropin dependent precocious puberty in girls.